4BB 4basebio PLC

6.913USD525.00 GBp · LSE0.00%Mkt Cap: 132.61M USDP/E: —

4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and sale of synthetic DNA and RNA products in Europe, the United States, and internationally. It offers hpDNA, a double s…

Key Statistics

Company
Market Cap132.61M USD
Enterprise Value119.36M USD
Revenue (TTM)1.03M USD
Gross Profit1.28M USD
Net Income (TTM)-22.26M USD
Revenue/Share0.07 USD
Last Price6.913 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees140
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINGB00BMCLYF79
Valuation
P/E (Trailing)—
P/E (Forward)-6.53
PEG—
EV/EBITDA-5.56
EV/Revenue116.05
P/S128.94
P/B64.02
EPS (TTM)-1.53 USD
EPS (Forward)-1.06 USD
52W Range
0.000064% of range10.80
52W High10.80 USD
52W Low0.0000 USD
Profitability
Gross Margin57.53%
Oper. Margin-2201.92%
EBITDA Margin0.00%
Profit Margin-998.52%
ROE-167.19%
ROA-57.21%
ROIC-177.22%
ROCE-62.36%
Growth
Revenue Growth-77.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-20.53M USD
CapEx (TTM)2.16M USD
FCF Margin-1621.72%
FCF Yield-12.58%
Net Debt11.93M USD
Net Debt/EBITDA-0.56
Net Debt/FCF—
Balance Sheet
Debt/Equity1.65
Current Ratio5.98
Quick Ratio5.17
Book Value/Sh0.11 USD
Cash/Share1.19 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)14.88 USD
Upside (mean)+115.2%
Target Range12.38 USD – 19.09 USD
12.38+115.2% to mean19.09
# Analysts3
Ownership
Shares Out.15.48M
Float5.74M
Insiders50.32%
Institutions21.44%
Technical
SMA 506.997 (-1.2%)
SMA 2006.811 (+1.5%)
Beta0.81
S&P 52W Chg12.08%
Avg Vol (30d)726
Avg Vol (10d)592
Technical Indicators
RSI (14)38.3
MACD-2.4091
MACD Signal-1.8263
MACD Hist.-0.5828
BB Upper7.010 USD
BB Middle6.943 USD
BB Lower6.876 USD
BB Width1.94%
ATR (14)0.3626 USD
Vol Ratio (20d)0.09x

About 4basebio (LON: 4BB)

›

4basebio (LON: 4BB) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 140 employees.

The shares were at 525.00 GBp on 19 November 2026, down 27.6% over 52 weeks.

Its market capitalisation is 100.70M GBP.

4basebio reports return on equity of -167.2% and revenue down 77.7% year over year.

Its debt exceeds its cash by 9.06M GBP, a debt-to-equity ratio of 1.65. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 3 analysts cover the stock; their mean price target of 1130.00 GBp is 115.2% above the current price.